Novel Application of Lutetium-177-Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic Synovial Sarcoma

IF 1.4 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of Medical Imaging and Radiation Oncology Pub Date : 2025-03-21 DOI:10.1111/1754-9485.13838

Rhiannon S. McBean, Annaleis M. Tatkovic, Sepinoud Firouzmand, Francis Tomlinson, Paul Eliadis, David C. Wong

{"title":"Novel Application of Lutetium-177-Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic Synovial Sarcoma","authors":"Rhiannon S. McBean, Annaleis M. Tatkovic, Sepinoud Firouzmand, Francis Tomlinson, Paul Eliadis, David C. Wong","doi":"10.1111/1754-9485.13838","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Intracranial synovial sarcoma is exceedingly rare, with only 24 cases reported in the literature. Given prostate specific membrane antigen (PSMA) expression is found in the neovascular endothelium of solid tumours, including sarcomas, Lutetium-177-PSMA (LuPSMA) presents a potential therapeutic option. The case presented here describes the first application of LuPSMA in a patient with synovial sarcoma. Our patient, a 27-year-old female underwent seven LuPSMA treatment cycles over the last 8 months of her life. Disease stability and prolongation in time to progression was observed across the treatment course with subjective tumour regression also seen after two cycles. Overall, our initial experience with this novel approach demonstrates proof-of-principle of LuPSMA treatment beyond prostate cancer, for patients with other PSMA-expressing cancer diseases.</p>\n </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 3","pages":"381-385"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Imaging and Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1754-9485.13838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Intracranial synovial sarcoma is exceedingly rare, with only 24 cases reported in the literature. Given prostate specific membrane antigen (PSMA) expression is found in the neovascular endothelium of solid tumours, including sarcomas, Lutetium-177-PSMA (LuPSMA) presents a potential therapeutic option. The case presented here describes the first application of LuPSMA in a patient with synovial sarcoma. Our patient, a 27-year-old female underwent seven LuPSMA treatment cycles over the last 8 months of her life. Disease stability and prolongation in time to progression was observed across the treatment course with subjective tumour regression also seen after two cycles. Overall, our initial experience with this novel approach demonstrates proof-of-principle of LuPSMA treatment beyond prostate cancer, for patients with other PSMA-expressing cancer diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

镥-177-前列腺特异性膜抗原（LuPSMA）放射性配体疗法在转移性滑膜肉瘤中的新应用。

颅内滑膜肉瘤极为罕见，文献报道仅有24例。鉴于前列腺特异性膜抗原（PSMA）在实体肿瘤（包括肉瘤）的新生血管内皮中表达，Lutetium-177-PSMA （LuPSMA）提供了一种潜在的治疗选择。本病例介绍了LuPSMA在滑膜肉瘤患者中的首次应用。我们的患者，一名27岁的女性，在她生命的最后8个月里经历了7次LuPSMA治疗周期。在整个治疗过程中观察到疾病的稳定性和进展时间的延长，在两个周期后也观察到主观肿瘤消退。总的来说，我们对这种新方法的初步经验证明了LuPSMA治疗前列腺癌以外的其他表达psma的癌症疾病的原理证明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Medical Imaging and Radiation Oncology 医学-核医学

CiteScore

3.30

自引率

6.20%

发文量

133

审稿时长

6-12 weeks

期刊介绍： Journal of Medical Imaging and Radiation Oncology (formerly Australasian Radiology) is the official journal of The Royal Australian and New Zealand College of Radiologists, publishing articles of scientific excellence in radiology and radiation oncology. Manuscripts are judged on the basis of their contribution of original data and ideas or interpretation. All articles are peer reviewed.